Specific content on stage IV or metastatic cancer treatment costs (drugs, hospital, management), particularly immunotherapy + insurance help.
In 2026, most patients pay between $300 and $3,000 per month depending on their plan, deductible, and location. This complete guide breaks down Keytruda prices with and without insurance, Medicare coverage, patient assistance programs, and expert insights to help Americans save on cancer treatment costs.
Imfinzi Cost in the USA 2025: What Patients Need to Know Imfinzi (durvalumab) has become a vital immunotherapy option for patients with lung cancer in the United States, but its price remains a major concern in 2025. The average cost of a single Imfinzi infusion is estimated at $10,000–$12,000, which means that annual treatment expenses can easily exceed $140,000 per year before insurance or assistance programs are applied. For patients and caregivers, understanding the true cost of Imfinzi involves more than just the drug’s wholesale price. Factors such as insurance coverage, Medicare Part B rules, infusion center administration fees, and manufacturer co-pay assistance all play a role in determining what you will actually pay out-of-pocket. The good news is that programs like AstraZeneca Access 360 and patient savings support can dramatically lower costs, sometimes reducing co-pays to as little as $0 for eligible patients. In this updated 2025 guide, we provide detailed price breakdowns, comparisons with other immunotherapies like Keytruda and Opdivo, insurance coverage insights, and 20 frequently asked questions (FAQs) to help you navigate Imfinzi’s financial impact.
In 2025, cancer treatment costs in the United States remain among the highest in the world, with several oncology drugs carrying annual price tags well over $150,000. This article breaks down the Top 10 most expensive cancer drugs in the U.S., comparing per-dose and per-year costs, highlighting manufacturers, and explaining what patients actually pay after insurance. From blockbuster immunotherapies like Keytruda and Imfinzi to groundbreaking CAR-T and gene therapies priced at nearly half a million dollars per treatment, this guide provides a clear look at the latest pricing landscape and practical insights for patients navigating financial support programs.
Keytruda (pembrolizumab) is one of the most widely prescribed immunotherapy drugs for cancer, but its cost continues to be a major concern for patients in 2025. On average, a single 200 mg intravenous dose is estimated at around $11,700 under Medicare ASP pricing, while a 6-week 400 mg dose carries a published list price of $23,590. Depending on the treatment plan, annual costs can exceed $200,000 per patient. In 2025, Merck also introduced a new subcutaneous formulation (Keytruda QLEX), which offers shorter administration times but could bring different pricing models compared to IV dosing. Insurance coverage, Medicare billing rules, and patient assistance programs remain critical factors in determining real out-of-pocket costs.
Keytruda (pembrolizumab) is one of the most widely prescribed immunotherapy drugs for cancer — but its high cost often leaves patients wondering how much they will actually pay. In 2025, the average list price for a single Keytruda infusion is around $11,000–$12,000, with annual costs exceeding $190,000 before insurance. Fortunately, Medicare, Medicaid, and private insurers cover most of these expenses, and copay assistance programs can reduce patient costs to as little as $25 per infusion. This guide explains the real monthly price of Keytruda in 2025, how insurance coverage works, and practical tips patients can use to lower out-of-pocket expenses.
Opdivo (nivolumab) is one of the most widely used immunotherapy drugs in the United States, but its cost can be overwhelming for many cancer patients. In 2025, the monthly price of Opdivo ranges from $15,000 to over $20,000 before insurance, depending on dosage and treatment schedule. The good news is that Medicare, private insurance, and financial assistance programs can reduce these expenses significantly, sometimes lowering patient out-of-pocket costs to only a few hundred dollars per month. This guide explains the real cost of Opdivo per month, how insurance coverage works, and what assistance options are available to help patients manage treatment expenses.
In 2025, the cost of Opdivo (Nivolumab) in the United States continues to be a major concern for cancer patients and families. With monthly expenses ranging from $12,000 to $26,000 without insurance, many wonder how they can afford this life-saving immunotherapy. This article explains the true price of Opdivo in 2025, how much insurance covers, available patient assistance programs, and how Opdivo compares to other cancer treatments like Keytruda and Yervoy. You’ll also find updated FAQs with trusted links to help patients make informed financial and medical decisions.
Keytruda (pembrolizumab) has transformed cancer treatment, but its price tag remains one of the highest in oncology. In 2025, the average monthly cost of Keytruda in the United States is estimated at $15,000 to $16,000, depending on the dosing schedule. While list prices are staggering, most patients do not pay this full amount thanks to insurance coverage, Medicare benefits, and financial assistance programs. Still, questions like “How much does Keytruda cost per month?” and “Why is Keytruda so expensive?” are critical for patients, caregivers, and policymakers navigating the realities of modern cancer care.